High Tide Reports Record-Breaking Third Quarter 2026 Financial Results
High Tide Inc. reported record Q3 2026 results: $199M revenue, $52.7M gross profit, $16.2M adjusted EBITDA, and $12.7M net income. Canna Cabana's market share grew to 14%. Revenue increased 33% YoY and 11% sequentially. Remexian distributed 10.2 tonnes of medical cannabis in Germany, up 62% YoY.
How this was made
The 30-second read
Why it matters
The earnings beat and record cash generation suggest near‑term upside, while the expansion in Germany via Remexian adds international growth exposure.
Market read
First‑report earnings release with strong growth metrics; likely to move HITI and influence the cannabis sector.
What to watch
Currency exposure in Germany and reliance on Canna Cabana's market share could be risk factors.
Background
High Tide Inc. (Nasdaq: HITI, TSXV: HITI) released its unaudited Q3 2026 financials, showing record revenue and profitability across its retail and medical cannabis segments.
Ticker impact
High Tide reported record Q3 2026 revenue of $199M, adjusted EBITDA of $16.2M and net income of $12.7M, a significant beat and growth versus prior year.
Potential short‑term price rally of 5‑10% as investors price in higher growth trajectory.
Revenue up 33% YoY, EBITDA margin at 8.2% (highest in 12 quarters), and free cash flow up 373% indicate robust operational leverage.
Market effects
Positive earnings may lift broader Canadian cannabis sector and peers like Canopy Growth and Aurora.
Strengthens investor sentiment in North American cannabis stocks, especially TSXV‑listed companies.
Highlights growth potential of cannabis retail internationally, supporting European medical cannabis exposure.
Counterpoint
Valuation may already price in growth; any slowdown in regulatory approvals could pressure the stock.
Key entities
- companyHigh Tide Inc.
Cannabis retailer and medical cannabis distributor.
- brandCanna Cabana
High Tide's Canadian retail chain.
- brandRemexian
High Tide's medical cannabis distribution business in Germany.
